Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.56 |
| ▸ | DRD1 | P21728 | 2/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MC4R | P32245 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12658796 | 0.82 | CYP2D6 (0.48) | CYP2D6KCNH2HRH3MC4R | |
| SCHEMBL14198387 | 0.82 | DRD2 (0.60) | CYP2D6HTR2AHTR2C | |
| SCHEMBL2554948 | 0.81 | OPRM1 (0.53) | CHRM2ADRA2ACYP2D6CHRM1DRD1 | |
| SCHEMBL3393165 | 0.81 | CHRM2 (0.53) | CHRM2ADRA2ACYP2D6CHRM1DRD1 | |
| SCHEMBL3392214 | 0.81 | CARM1 (0.63) | CHRM2ADRA2ACYP2D6CHRM1DRD1 | |
| SCHEMBL14198386 | 0.81 | BACE1 (0.50) | CYP2D6HTR2AHTR2C | |
| SCHEMBL677532 | 0.80 | IDO1 (0.52) | CYP2D6 | |
| SCHEMBL8674414 | 0.80 | IDO1 (0.52) | CYP2D6 | |
| SCHEMBL13890145 | 0.80 | BACE1 (0.46) | CYP2D6 | |
| SCHEMBL14431944 | 0.79 | CYP2D6 (0.47) | CHRM2ADRA2ACYP2D6CHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742707-A4 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7355042-B2 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355042-B2 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1443929-A4 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2008-02-06 | — | — | EP | disclosed |
| US-7317030-B2 | Compounds as inhibitors of cell proliferation and viral infections | 4SC AG (DE) | 2008-01-08 | — | — | US | disclosed |
| US-7317026-B2 | Sleep disorders; side effect reduction ; antihistamine antagonist | HYPNION, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317026-B2 | Sleep disorders; side effect reduction ; antihistamine antagonist | HYPNION, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7189757-B2 | Treatment of sleep disorders using CNS target modulators | HYPNION, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189757-B2 | Treatment of sleep disorders using CNS target modulators | HYPNION, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1742707-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | Hypnion, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005103041-A9 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005103041-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005082868-A1 | COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND VIRAL INFECTIONS | 4SC AG (DE) | 2005-09-09 | — | — | WO | disclosed |
| US-20050080265-A1 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050009730-A1 | Treatment of cns disorders using cns target modulators | HYPNION, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2003032912-A9 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2005-01-06 | — | — | WO | disclosed |
| EP-1443929-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | Hypnion, Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040142972-A1 | CNS target modulators | HYPNION, INC. | 2004-07-22 | — | — | US | disclosed |
| US-20030187021-A1 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003032912-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009730-A1 | Treatment of cns disorders using cns target modulators | HCRTR2, CNR2, CNR1 | CHRM2 68/4885ADRA2A 634/4885CYP2D6 1239/4885 |
| US-20030187021-A1 | Treatment of CNS disorders using CNS target modulators | HCRTR2, CNR2, CNR1 | CHRM2 68/4885ADRA2A 634/4885CYP2D6 1239/4885 |
| US-20050080265-A1 | Treatment of CNS disorders using CNS target modulators | HCRTR2, HRH3, HCRTR1 | CHRM2 113/4885ADRA2A 693/4885CYP2D6 1176/4885 |
| US-20040142972-A1 | CNS target modulators | HCRTR2, CNR2, CNR1 | CHRM2 50/4885ADRA2A 424/4885CYP2D6 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.